Tabár, LászlóLászlóTabárDean, Peter BPeter BDeanLee Tucker, FFLee TuckerHSIU-HSI CHENSmith, Robert ARobert ASmithDuffy, Stephen WStephen WDuffyChiu, Sherry Yueh-HsiaSherry Yueh-HsiaChiuKu, May Mei-ShengMay Mei-ShengKuFan, Chiao-YunChiao-YunFanYen, Amy Ming-FangAmy Ming-FangYen2023-03-202023-03-202022-090720-048Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/629393As we have previously demonstrated, breast cancers originating in the major lactiferous ducts and propagating through the process of neoductgenesis are a distinct subtype of invasive breast cancers, although by current practice they are placed within the group termed ductal carcinoma in situ (DCIS) and are consequently underdiagnosed and undertreated. Imaging biomarkers provide a reliable indication of the site of origin of this breast cancer subtype (Ductal Adenocarcinoma of the breast, DAB) and have excellent concordance with long-term patient outcome. In the present paper, the imaging biomarkers of DAB are described in detail to encourage and facilitate its recognition as a distinct, invasive breast cancer subtype.enBiomarkers; Breast carcinoma in situ; Breast neoplasms; Early detection of cancer; Histopathology technology; Interdisciplinary communication; Mammography; Margins of excision; Pathologists; Patient care; Precision oncologyjournal article10.1016/j.ejrad.2022.110394357519402-s2.0-85132784777WOS:000817974600001https://api.elsevier.com/content/abstract/scopus_id/85132784777